Decreasing leptin levels have been suggested to alleviate AD-related cellular changes in rabbit organotypic slices [87] and in human neuroblastoma cell culture [88, 89], suggesting that lowered leptin levels detected in AD subjects can be a possible target for developing supplementation therapies for reducing the progression of AD. The gene discussed is LEP; the disease is neuroblastoma.